Abstract
Historically, clinicians have had few resources beyond empiric tools derived from population-based treatment algorithms and patient/family interviews to inform the "best choice" for psychopharmacologic intervention. Previously unappreciated interindividual variance in activity of cytochrome P450 enzymatic activity can lead to abnormal metabolism of many psychotropics and poor outcomes. Fortunately, advances in our understanding and application of psychiatric pharmacogenomic information have the potential to improve the quality of medical care for children at the level of the individual prescription.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 53-58 |
| Number of pages | 6 |
| Journal | Primary Psychiatry |
| Volume | 17 |
| Issue number | 5 |
| State | Published - May 2010 |
ASJC Scopus subject areas
- Psychiatry and Mental health